IBIO, INC. (IBIO) Spending and interest coverage
- R&D / revenue · 12 months: Value 19643.00%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1373.00%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 19643.00% | Research and development expense / revenue. Period ending 2026-06-30. $19.64M ÷ $100.00K × 100 ≈ 19643.00% |
| Stock-based compensation / revenue · 12 months | 1373.00% | Share-based compensation / revenue. Period ending 2026-06-30. $1.37M ÷ $100.00K × 100 ≈ 1373.00% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 19.64M USD | Research and Development Expense |
| Revenue | 100.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 1.37M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -35.14M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.64M | $100.00K | $1.37M | $-35.14M | (m) | 19643.00% | 1373.00% | (m) | (m) |
| 2026-03-31 | $14.31M | $300.00K | $1.22M | $-28.96M | (m) | 4769.33% | 407.67% | (m) | (m) |
| 2025-12-31 | $12.96M | $300.00K | $1.22M | $-25.47M | (m) | 4320.00% | 405.33% | (m) | (m) |
| 2025-09-30 | $10.56M | $500.00K | $1.44M | $-20.45M | (m) | 2111.40% | 287.60% | (m) | (m) |
| 2025-06-30 | $8.31M | $400.00K | $1.53M | $-18.60M | (m) | 2078.00% | 382.50% | (m) | (m) |
| 2025-03-31 | $6.23M | $375.00K | $1.62M | $-16.81M | (m) | 1660.80% | 432.00% | (m) | (m) |
| 2024-12-31 | $5.23M | $375.00K | $1.71M | $-15.56M | (m) | 1393.60% | 455.20% | (m) | (m) |
| 2024-09-30 | $4.88M | $175.00K | $1.69M | $-15.64M | (m) | 2790.86% | 964.57% | (m) | (m) |
| 2024-06-30 | $5.18M | $225.00K | $2.04M | $-16.63M | (m) | 2304.44% | 905.78% | (m) | (m) |
| 2024-03-31 | $6.40M | (m) | $2.12M | $-18.19M | $129.00K | (m) | (m) | -141.01× | Reported |
| 2023-12-31 | $8.14M | (m) | $3.26M | $-20.73M | $112.00K | (m) | (m) | -185.12× | Reported |
| 2023-09-30 | $9.38M | $50.00K | $3.93M | $-26.81M | $109.00K | 18770.00% | 7868.00% | -245.96× | Reported |
| 2023-06-30 | $10.33M | $0.00 | $4.39M | $-29.34M | $83.00K | (m) | (m) | -353.53× | Reported |
| 2023-03-31 | $19.43M | (m) | $5.12M | $-54.82M | $291.00K | (m) | (m) | -188.40× | Reported |
| 2022-12-31 | $20.06M | $2.00M | $4.80M | $-55.44M | $506.00K | 1001.15% | 239.62% | -109.57× | Reported |
| 2022-09-30 | $19.14M | $2.30M | $4.78M | $-52.10M | (m) | 832.67% | 207.83% | (m) | (m) |
| 2022-06-30 | $17.73M | $2.38M | $4.38M | $-49.69M | $1.41M | 743.98% | 183.68% | -35.19× | Reported |
| 2022-03-31 | $14.49M | $2.81M | $3.79M | $-42.23M | $1.80M | 515.11% | 134.87% | -23.46× | Reported |
| 2021-12-31 | $11.60M | $1.64M | $2.89M | $-37.25M | $2.16M | 709.17% | 177.00% | -17.23× | Reported |
| 2021-09-30 | $10.64M | $2.17M | $2.06M | $-33.16M | $2.45M | 489.78% | 94.66% | -13.54× | Reported |
| 2021-06-30 | $9.99M | $2.37M | $1.59M | $-31.11M | $2.45M | 421.30% | 66.89% | -12.68× | Reported |
| 2021-03-31 | $7.12M | $3.00M | $1.21M | $-24.60M | $2.46M | 237.17% | 40.33% | -10.02× | Reported |
| 2020-12-31 | $5.55M | $2.33M | $899.00K | $-21.46M | $2.46M | 238.27% | 38.57% | -8.72× | Reported |
| 2020-09-30 | $4.00M | $1.94M | $671.00K | $-17.07M | $2.46M | 206.08% | 34.59% | -6.94× | Reported |
| 2020-06-30 | $3.21M | $1.64M | $388.00K | $-14.00M | $2.47M | 196.15% | 23.69% | -5.68× | Reported |
| 2020-03-31 | $4.49M | $1.31M | $227.00K | $-15.13M | $2.33M | 341.81% | 17.29% | -6.51× | Reported |
| 2019-12-31 | $4.94M | $1.74M | $213.00K | $-14.83M | $2.18M | 283.37% | 12.21% | -6.79× | Reported |
| 2019-09-30 | $5.33M | $2.08M | $236.00K | $-15.69M | $2.04M | 255.98% | 11.34% | -7.68× | Reported |
| 2019-06-30 | $5.47M | $2.02M | $241.00K | $-15.79M | $1.90M | 271.26% | 11.94% | -8.31× | Reported |
| 2019-03-31 | $4.89M | $1.31M | $375.00K | $-15.68M | $1.90M | 372.30% | 28.54% | -8.24× | Reported |
| 2018-12-31 | $4.41M | $865.00K | $509.00K | $-15.40M | $1.91M | 509.25% | 58.84% | -8.07× | Reported |
| 2018-09-30 | $4.13M | $367.00K | $638.00K | $-14.82M | $1.91M | 1123.98% | 173.84% | -7.75× | Reported |
| 2018-06-30 | $3.99M | $444.00K | $770.00K | $-14.23M | $1.92M | 897.75% | 173.42% | -7.43× | Reported |
| 2018-03-31 | $4.06M | $500.00K | $874.00K | $-14.14M | $1.92M | 811.20% | 174.80% | -7.37× | Reported |
| 2017-12-31 | $4.23M | $459.00K | $898.00K | $-14.58M | $1.92M | 920.70% | 195.64% | -7.59× | Reported |
| 2017-09-30 | $4.28M | $381.00K | $950.00K | $-14.48M | $1.93M | 1123.88% | 249.34% | -7.52× | Reported |
| 2017-06-30 | $4.12M | $394.00K | $1.01M | $-14.27M | $1.93M | 1044.92% | 256.35% | -7.40× | Reported |
| 2017-03-31 | $3.86M | $522.00K | $1.02M | $-13.17M | $1.93M | 739.08% | 195.02% | -6.82× | Reported |
| 2016-12-31 | $3.77M | $864.00K | $1.11M | $-12.30M | $1.77M | 436.34% | 128.24% | -6.94× | Reported |
| 2016-09-30 | $3.42M | $923.00K | $1.18M | $-11.23M | $1.29M | 371.07% | 127.95% | -8.71× | Reported |
| 2016-06-30 | $3.16M | $948.00K | $1.25M | $-9.89M | $807.00K | 332.91% | 131.33% | -12.26× | Reported |
| 2016-03-31 | $3.07M | $989.00K | $1.16M | $-9.04M | (m) | 310.11% | 117.69% | (m) | (m) |
| 2015-12-31 | $2.83M | $959.00K | $1.09M | $-7.65M | (m) | 295.52% | 113.76% | (m) | (m) |
| 2015-09-30 | $2.86M | $1.19M | $990.00K | $-7.06M | (m) | 240.02% | 83.05% | (m) | (m) |
| 2015-06-30 | $3.50M | $1.85M | $914.00K | $-6.67M | (m) | 188.82% | 49.38% | (m) | (m) |
| 2015-03-31 | $3.15M | $1.74M | $930.00K | $-5.92M | (m) | 180.98% | 53.45% | (m) | (m) |
| 2014-12-31 | $2.68M | $1.39M | $1.03M | $-5.53M | (m) | 192.45% | 74.12% | (m) | (m) |
| 2014-09-30 | $2.53M | $1.02M | $1.09M | $-5.50M | (m) | 247.17% | 106.74% | (m) | (m) |
| 2014-06-30 | $1.90M | $205.00K | $1.07M | $-3.84M | $0.00 | 925.85% | 524.39% | (m) | Reported |
| 2014-03-31 | $2.45M | $617.00K | $1.09M | $-3.99M | $42.00K | 396.60% | 176.50% | -95.02× | Reported |
| 2013-12-31 | $2.73M | $617.00K | $1.10M | $-4.56M | $57.00K | 443.27% | 178.77% | -79.95× | Reported |
| 2013-09-30 | $2.81M | $617.00K | $1.04M | $-4.62M | $75.00K | 454.78% | 169.21% | -61.56× | Reported |
| 2013-06-30 | $3.43M | $1.01M | $1.26M | $-6.67M | $90.00K | 340.71% | 125.42% | -74.08× | Reported |
| 2013-03-31 | $3.52M | $741.60K | $1.62M | $-7.51M | $66.22K | 474.56% | 217.85% | -113.44× | Reported |
| 2012-12-31 | $4.20M | $1.11M | $1.96M | $-7.83M | $69.33K | 376.83% | 175.99% | -112.99× | Reported |
| 2012-09-30 | $4.70M | $1.35M | $2.76M | $-8.81M | $68.68K | 349.02% | 204.85% | -128.31× | Reported |
| 2012-06-30 | $4.98M | $1.28M | $2.61M | $-9.33M | $62.85K | 389.95% | 204.52% | -148.41× | Reported |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $3.08M | $520.08K | $3.90M | $-9.65M | $50.50K | 592.89% | 749.37% | -191.16× | Reported |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |